Treeline Biosciences announced plans to enter public markets via a reverse merger with Standard BioTools, with the combined company expected to trade on the Nasdaq under the ticker symbol TRLN. The deal is designed to provide Treeline and its early oncology pipeline with cash estimated to fund operations into 2029. Under deal terms, Standard BioTools stockholders are projected to hold about 16% of the combined company, while Treeline investors are expected to own about 84%. Treeline brings a trio of early-stage experimental oncology programs, including TLN-121 (BCL6 degrader), TLN-372 (pan-KRAS inhibitor), and TLN-254, which is already approved in China for relapsed or refractory peripheral T-cell lymphoma. Treeline and Standard BioTools said the combination also involves a contingent value right tied to proceeds from sales of Standard BioTools assets. Standard BioTools said it will not continue its mass cytometry and microfluidics businesses post-closing and is exploring options to maximize shareholder value.